This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations. Improving survival and ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...